Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
Plus Therapeutics, Inc. has announced the successful completion of the ReSPECT-LM Phase 1 trial, which evaluated the safety and efficacy of intrathecally administered Rhenium (186Re) Obisbemeda for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results